OOIR: Observatory of International Research

Papers

(The TQCC of Neurology-Neuroimmunology & Neuroinflammation is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Complement Factor I Gene Variant as a Treatable Cause of Recurrent Aseptic Neutrophilic Meningitis	458
CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent	132
COVID-19 Among Patients With Multiple Sclerosis	129
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	108
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	106
Immune-Mediated Rippling Muscle Disease Associated With Thymoma and Anti-MURC/Cavin-4 Autoantibodies	100
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis	91
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	90
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	80
Dysregulation of the Kynurenine Pathway in Relapsing Remitting Multiple Sclerosis and Its Correlations With Progressive Neurodegeneration	78
Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10–Producing Cell Populations During Treatment	77
Pediatric MOG-Ab–Associated Encephalitis	75
Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis	64
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors	64
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	62
Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes	60
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception	60
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis	56
More Efficient Complement Activation by Anti–Aquaporin-4 Compared With Anti–Myelin Oligodendrocyte Glycoprotein Antibodies	55
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	54
Pure Relapsing Short Myelitis	54
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	52
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	52
Progressive Encephalomyelopathy in an Older Man	48
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	48

Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy	48
Neurosarcoidosis of the Cauda Equina	47
Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation	46
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	43
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	42
Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity	42
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab	41
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	41
Immune-Mediated Rippling Muscle Disease Associated With Thymoma and Anti-MURC/Cavin-4 Autoantibodies	40
Impaired Presynaptic Function Contributes Significantly to the Pathology of Glycine Receptor Autoantibodies	40
CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis	39
Vascular Involvement in Neurosarcoidosis	39
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	39
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	39
Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma	39
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment	38
Abatacept Induces Long-Term Reconstitution of the B-Cell Niche in a Patient With CTLA-4 Haploinsufficiency	38
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	38
Anti-IgLON5 Disease 10 Years Later	37
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	37
Clinical and Paraclinical Characterizations, Management, and Prognosis in DPPX Antibody-Associated Encephalitis	37
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	37
Clinical Characterization and Prognostic Risk Factors of Susac Syndrome	37
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	37
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	36
Lesional Antibody Synthesis and Complement Deposition Associate With De Novo Antineuronal Antibody Synthesis After Spinal Cord Injury	35
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	34
Synthetic Cell-Based Immunotherapies for Neurologic Diseases	34
Anti-LGI1 Encephalitis With Co-occurring IgLON5 Antibodies	34
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	33
Effect of Teriflunomide on Cells From Patients With Human T-cell Lymphotropic Virus Type 1–Associated Neurologic Disease	33
Teenager With Recurrent Ataxia, Ophthalmoplegia, and Encephalopathy Associated With Demyelination	33
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year	33
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis	33
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	32
Infratentorial MRI Findings in Rasmussen Encephalitis Suggest Primary Cerebellar Involvement	32
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	32
Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy	31
Opsoclonus-Ataxia Syndrome in a Patient With Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors	31
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	31
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	31
PET Study of Microglial Activation in Kleine-Levin Syndrome	30
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	30
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	29
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	29
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 ⁺ T-Cell Proliferation in Patients With Multiple Sclerosis	29
Acknowledgment to Reviewers	29
Treatment of Cerebral Histiocytosis With Low Dose of Cobimetinib	29
Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores	29
Neuropsychological Testing in Autoimmune Encephalitis	29

Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis	28
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	28
Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS	28
Retinal Optical Coherence Tomography in Neuromyelitis Optica	28
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	28
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	28
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone	28
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	28
Multimodal Investigation of Neuroinflammation in Aviremic Patients With HIV on Antiretroviral Therapy and HIV Elite Controllers	27
Risk of Getting COVID-19 in People With Multiple Sclerosis	27
COVID-19 Among Patients With Multiple Sclerosis	27
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	26
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder	26
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	26
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections	26
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	26
Therapies in Stiff-Person Syndrome	26
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction	26
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom	26
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis	26
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	26
Late-Onset Anti-GABA _B Receptor Encephalitis	25
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	25
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease	25
Antibody-Negative Autoimmune Encephalitis	25
Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy	24
Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?	24
Tuberculous Meningitis or Neurosarcoidosis—a Diagnostic Quandary	24
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	24
Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone	23
Encephalitis and Myelitis in a Young Woman	23
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion	23
Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis	23
The Pursuit of Precision in Paraneoplastic Neurologic Disease	23
Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders	22
Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures	22
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2	22
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	21
Young-Onset Alzheimer Dementia Due to a Novel Pathogenic Presenilin 1 Variant Initially Misdiagnosed as Autoimmune Encephalitis	21
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	21
Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders	20
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis	20
Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis	20
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis	20
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	20
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	20
Advancing Knowledge in CNS Vasculitis	19
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	19
Alterations of Thymus-Derived Tregs in Multiple Sclerosis	19
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	19
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	19
Acute Paresthesia and Ataxia in a Child	19
Progressive Encephalomyelitis With Rigidity and Myoclonus With Glycine Receptor and GAD65 Antibodies	19
Should We Measure CSF Complement Levels in Patients With MOGAD?	19
Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis	19
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis	19
“Lupus Myelitis” Revisited	19
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection	18
Treatment With Erythropoietin for Patients With Optic Neuritis	18
Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages	18
Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis	18
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	18
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis	18
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	18
Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings	18
Ocrelizumab Impairs the Phenotype and Function of Memory CD8 ⁺ T Cells	18
Fatigue in Survivors of Autoimmune Encephalitis	18
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	18
Cerebellar Ataxia With Anti-DNER Antibodies	18
Ravulizumab and Efgartigimod in Myasthenia Gravis	18
Neurologic Syndromes Related to Anti-GAD65	18
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	17
Electrolyte Imbalance in Anti-LGI1 Encephalitis	17
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	17
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	17
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	17
Relapsing White Matter Disease and Subclinical Optic Neuropathy	17
Network Damage Predicts Clinical Worsening in Multiple Sclerosis	17
Younger Age at Onset Is Associated With Worse Long-term Behavioral Outcomes in Anti-NMDA Receptor Encephalitis	17
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies	17